Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Drugmakers dance with autism

With monogenetic neurodevelopmental disorders similar to autism serving as starting points for several drug discovery programs, smaller biotechs are now joining big pharma in pursuing therapies to tackle this perplexing condition. Sarah Webb reports.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. Pinto, D. et al. Nature 466, 368–372 (2010).

    Article  CAS  Google Scholar 

  2. Berkel, S. et al. Nat. Genet. 42, 489–491 (2010).

    Article  CAS  Google Scholar 

  3. Guy, J. et al. Science 315, 1143–1147 (2007).

    Article  CAS  Google Scholar 

  4. Dölen, G. et al. Neuron 56, 955–962 (2007).

    Article  Google Scholar 

  5. Andari, E. et al. Proc. Natl. Acad. Sci. USA 107, 4389–4394 (2010).

    Article  CAS  Google Scholar 

  6. Ring, R.H. et al. Neuropharmacology 58, 69–77 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Reprints and Permissions

About this article

Cite this article

Webb, S. Drugmakers dance with autism. Nat Biotechnol 28, 772–774 (2010).

Download citation

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing